^
Association details:
| Biomarker: | BRAF G466E + NF1 Y2285fs*5 + NF1 Y2640fs*3 + TP53 D281Y |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of pembrolizumab in lung adenocarcinoma harboring non-V600E BRAF mutation: a case report
Published date:
03/30/2022
Excerpt:
The patient is a 79 years old male who performed diagnostic investigations in December 2019 due to recurrent dorsal pain....The diagnosis was lung adenocarcinoma….Comprehensive molecular profiling by next generation sequencing (NGS) identified the G466E BRAF mutation. Other cancer-related alterations founded were NF1 (Y2285fs*5; Y2640fs*3), TP53 (D281Y)....he continued pembrolizumab treatment. The last PET CT performed 2 months later showed bone complete metabolic response and further partial metabolic response on lung, pleural and adrenal disease.
DOI:
doi: 10.21037/pcm-21-22
